OOIR: Observatory of International Research

Papers

(The H4-Index of British Journal of Haematology is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma	111
Updates on targeted therapies for acute myeloid leukaemia	95
Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry	94
Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID‐19): evidence of acute and sustained endothelial cell activation	93
SARS‐CoV‐2‐induced remission of Hodgkin lymphoma	92
Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations	84
T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies	80
Disseminated intravascular coagulation: epidemiology, biomarkers, and management	80
Hemophagocytic lymphohistiocytosis‐like toxicity (carHLH) after CD19‐specific CAR T‐cell therapy	74
Exacerbation of immune thrombocytopenia following COVID‐19 vaccination	73
Impact of COVID‐19 on red blood cell rheology	69
Chimeric antigen receptor (CAR) natural killer (NK)‐cell therapy: leveraging the power of innate immunity	67
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma	65
Molecular profiling in diffuse large B‐cell lymphoma: why so many types of subtypes?	60
COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies	58
A national service for delivering CD19 CAR‐Tin large B‐cell lymphoma – The UK real‐world experience	58
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma	57
MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a pros	55
Graft‐versus‐host disease risk after chimeric antigen receptor T‐cell therapy: the diametric opposition of T cells	53
COVID‐19‐induced endotheliitis: emerging evidence and possible therapeutic strategies	53
Immunogenicity and safety of the BNT162b2 mRNA COVID‐19 vaccine in haematopoietic stem cell transplantation recipients	52
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic mye	52
Vacuoles in neutrophil precursors in VEXAS syndrome: diagnostic performances and threshold	50
Serological SARS‐CoV‐2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID‐19 vaccine in haematological and oncological patients	49
Haemophagocytic lymphohistiocytosis and Epstein–Barr virus: a complex relationship with diverse origins, expression and outcomes	49

Thrombophilia testing: A British Society for Haematology guideline	46
Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising ant	46
Vaccine‐induced immune thrombotic thrombocytopenia (VITT) – a novel clinico‐pathological entity with heterogeneous clinical presentations	45
Non‐myeloablative human leukocyte antigen‐matched related donor transplantation in sickle cell disease: outcomes from three independent centres	44
COVID‐19 and immunothrombosis: emerging understanding and clinical management	44
Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis	43
Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma	43
Early mortality benefit with COVID‐19 convalescent plasma: a matched control study	42
Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome	41
Haematological management of major haemorrhage: a British Society for Haematology Guideline	41
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study	41
Physiological and pathophysiological mechanisms of hepcidin regulation: clinical implications for iron disorders	41
Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries	39
Eltrombopag added to immunosuppression for children with treatment‐naïve severe aplastic anaemia	39
Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials	39